Welcome to the WCN 2021 Interactive Program

The congress will officially run on Central European Time (CET) - Rome Time 
To convert the congress times to your local time 
Click Here

    Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A/Discussion at the end

     The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Virtual Platform

Browsing Over 213 Sessions

Scientific Session: MT (Main Topics)
Session Time
17:10 - 18:40
Room
Main Topic A
Chair(s)
  • Bruno Dubois (France)
Sponsored Symposium
Session Time
09:00 - 09:30
Room
Industry 1
Chair(s)
  • Alessandro Padovani (Italy)
Session Description
The early diagnosis of Alzheimer’s disease: defining the patient journey for a paradigm shift

Alzheimer’s disease (AD) is the most common form of dementia, affecting millions of people worldwide and causing major personal and family distress and socio-economic burden. The presentation of AD encompasses a continuum that extends from asymptomatic individuals with pathological evidence of AD to patients with mild cognitive impairment (MCI) due to AD and finally patients with AD dementia. Pathological hallmarks of AD, β-amyloid plaques and neurofibrillary tangles may be detectable in the brain decades before clinical symptoms. In this context substantial technological advances in neuroimaging (MRI and PET) and CSF analysis allowed the development of biomarkers related to neurodegeneration, cerebral β-amyloid deposition, and tau-related pathology, increasing diagnostic accuracy and favoring the identification of early AD patients.
A timely and accurate diagnosis in the early stages of disease is critical for prognosis and advanced-care planning, which requires coordination between the patient, caregivers, family members, HCPs, specialists, social services and payers.
During the “Meet the Expert” the crucial theme of AD early diagnosis will be presented, discussing different steps of diagnostic journey including the relevance of clinical and biomarker assessments. Key learnings, implications and recommendations will be shared on how to improve patient journey, supporting paradigm shift in AD.

Sponsored Symposium
Session Time
09:00 - 10:30
Room
Industry 1
Chair(s)
  • Cristina Tassorelli (Italy)
Session Description
Envisioning a more inclusive, diverse and equitable global migraine landscape: are we making progress?

During this symposium, we will consider the myriad social determinants of health in general and – focusing on migraine specifically – critique the current state of diversity in clinical studies. We will also review what the latest data tell us about the efficacy and tolerability of monoclonal antibodies targeting the calcitonin gene-related peptide pathway (CGRP mAbs) for migraine prevention across diverse patient subgroups, including different ethnicities, migraine characteristics and comorbidities.
We hope you will join us as we attempt to address this important question: are we making progress towards a more inclusive, diverse, and equitable global migraine landscape?

Sponsored Symposium
Session Time
10:45 - 11:30
Room
Industry 2
Chair(s)
  • Walter Maetzler (Germany)
Session Description
Rethinking clinical care in Parkinson’s disease
This webinar will feature a panel of three experts who will review a clinical case of a person living with Parkinson’s.
They will discuss current challenges in the management of this condition, including ‘OFF’ state, motor and non-motor symptoms, and the role of multidisciplinary led care to achieve the outcomes that are of value to people living with Parkinson’s and their support network. The session will finish with a live panel discussion along with audience Q&A.
This webinar is part of the Think Beyond medical education programme, developed in collaboration with international experts, for healthcare professionals, which aims to encourage us to THINK BEYOND our current understanding of Parkinson’s disease, our own perceptions of quality of life in people living with Parkinson’s, and challenge the status quo in Parkinson’s management.
The webinar and the Think Beyond programme are developed and funded by Kyowa Kirin International, plc.

Sponsored Symposium
Session Time
09:00 - 10:15
Room
Industry 1
Chair(s)
  • Claudio Gasperini (Italy)
Session Description
How to get away with MS: the 3 key leverages in disease management

This session consists of three topics as follow:
“Creative Writing”: a cognitive enhancing perspective chaired by Giacomo Pinelli and Emilio Portaccio
Cognitive decline is esteemed as a major debilitating symptom of Multiple Sclerosis (Ms), especially deficits in episodic memory and processing speed. Therapeutic arts have demonstrated considerable benefits for people facing a variety of chronic illnesses. Cognitive Health is fundamental to provide the correct balance for Multiple Sclerosis patients. It can be improved by several activities such as creative writing which helps people’s lives by keeping the mind active. Creative writing engages patient’s mind, piques creativity, sparks curiosity and stimulates critical thinking. Therapeutic arts are also a method for those with MS to connect with the world around them, helping to reduce feelings of isolation and loneliness.
Motor activity and cognitive function: the winning combination by Marcello Moccia and Claudia Fink
Individuals with Multiple Sclerosis (MS) regularly show deficits in motor and cognitive functions. In particular, MS patients experience several difficulties with balance, gait and disfunction in cognitive processing speed. These symptoms can occur simultaneously, affecting the rehabilitation outcomes. In order to improve MS people’s life and to reduce the common symptoms, rehabilitation activities are fundamental. A key strategy to face MS and to ameliorate the disease management is a double approach to enhance both motor activities and cognitive functions. 
The inside-out approach: living Ms through emotions by Marta Radaelli and Damiano Tullio
Multiple sclerosis can affect not just the body but also the emotions. MS can cause behavioural and emotional symptoms and a variety of factors can contribute to them. Remaining physically and mentally active may help regulate mood swings. The right combination of medication, clinical support, counselling and healthy lifestyle habits represent a good strategy to manage MS. Mindfulness and yoga can contribute to control emotions and can provide a healthy balance in MS people’s life. 

Session Time
17:10 - 18:10
Room
Teaching Course A
Chair(s)
  • James L. Bernat (United States of America)
Session Time
13:30 - 14:00
Room
Plenary
Chair(s)
  • William M. Carroll (Australia)
Sponsored Symposium
Session Time
11:00 - 11:30
Room
Industry 1
Chair(s)
  • Ralf Gold (Germany)
Session Description
Janssen Neuroscience Introducing PONVORY® (Ponesimod): A New Treatment to Help Address the Unmet Needs of active RMS

Introducing PONVORY® (ponesimod)
• Product characteristics
• OPTIMUM Phase III trial: PONVORY® vs teriflunomide
• Study design
• Clinical efficacy
• Safety profile
• Prescribing PONVORY®
• PONVORY® dosing
• Summary

Session Time
08:00 - 09:05
Room
Teaching Course A
Chair(s)
  • Max J. Hilz (Germany)
Session Time
08:00 - 09:00
Room
Teaching Course B
Chair(s)
  • Andrea Truini (Italy)
Scientific Session: MT (Main Topics)
Session Time
09:30 - 11:00
Room
Main Topic A
Chair(s)
  • Giancarlo Comi (Italy)